FDMT Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 104710 min ago

@ $27.97

Išleistas: 14 vas. 2024 @ 22:13

Grąža: -16.88%

Ankstesnis signalas: vas. 14 - 20:43

Ankstesnis signalas: Pirkimas

Grąža: 2.04 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	317 415
Vidutinė apimtis	1.21M
Rinkos kapitalizacija	1.19B
EPS	$0 ( 2024-03-20 )
Kita pelno data	( $-0.730 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-9.01
ATR14	$0.0280 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-16	Bizily Scott	Sell	1 250	Stock Option (Right To Buy)
2024-04-16	Bizily Scott	Sell	500	Stock Option (Right To Buy)
2024-04-16	Bizily Scott	Buy	1 250	Common Stock
2024-04-16	Bizily Scott	Buy	500	Common Stock
2024-04-16	Bizily Scott	Sell	1 750	Common Stock

INSIDER POWER
31.08
Last 99 transactions
Buy: 3 571 023 \| Sell: 1 811 773

Tūris Koreliacija

Ilgas: -0.14 (neutral)

Trumpas: 0.80 (moderate)

Signal:(50.646) Neutral

4D Molecular Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
AFYA	0.848
RMCF	0.839
GOEV	0.826
NTCT	0.826
SLM	0.821
IMGN	0.818
TRMK	0.817
NDAQ	0.817
PRCT	0.816
LSXMA	0.816

10 Labiausiai neigiamai susiję koreliacijos
ISDX	-0.838
ZIONP	-0.827
TRHC	-0.826
NVSAU	-0.823
KSICU	-0.822
IOAC	-0.821
GRBK	-0.815
XFIN	-0.813
VRIG	-0.812
BRIVU	-0.81

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

4D Molecular Koreliacija - Valiuta/Žaliavos

0.38
( neutral )

0.31
( neutral )

0.00
( neutral )

0.38
( neutral )

-0.29
( neutral )

-0.32
( neutral )

4D Molecular Finansinės ataskaitos

Annual	2023
Pajamos:	$20.72M
Bruto pelnas:	$14.97M (72.26 %)
EPS:	$-2.58

FY	2023
Pajamos:	$20.72M
Bruto pelnas:	$14.97M (72.26 %)
EPS:	$-2.58

FY	2022
Pajamos:	$3.13M
Bruto pelnas:	$-751 000 (-24.00 %)
EPS:	$-3.12

FY	2021
Pajamos:	$18.04M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-11.09

Financial Reports:

No articles found.

4D Molecular

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.